Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: No longer an option' but an ethical obligation

MLA

Brandao, Marianna, et al. “Neoadjuvant Treatment for Intermediate/High-Risk HER2-Positive and Triple-Negative Breast Cancers: No Longer an Option’ but an Ethical Obligation.” ESMO Open, 4 (3, 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1110018916&authtype=sso&custid=ns315887.

APA

Brandao, M., Reyal, F., Hamy, A. S., & Piccart-Gebhart, M. (2019). Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: No longer an option’ but an ethical obligation. ESMO Open, 4 (3.

Chicago

Brandao, Marianna, F. Reyal, Anne Sophie Hamy, and Martine Piccart-Gebhart. 2019. “Neoadjuvant Treatment for Intermediate/High-Risk HER2-Positive and Triple-Negative Breast Cancers: No Longer an Option’ but an Ethical Obligation.” ESMO Open, 4 (3. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1110018916&authtype=sso&custid=ns315887.